51 studies found for:    "Kidney Neoplasms" AND (woman OR women OR female)
Show Display Options
Rank Status Study
21 Completed Zinc Supplements in Lowering Cadmium Levels in Smokers
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Intervention: Dietary Supplement: zinc oxide
22 Completed
Has Results
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Drug: nicotine lozenge;   Drug: nicotine patch
23 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry
24 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
25 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
26 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Bladder Carcinoma;   Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Neoplasm;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma;   Urethral Carcinoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
27 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
28 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment
29 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
30 Recruiting A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Conditions: Non-small Cell Lung Cancer (NSCLC);   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Ovarian Carcinoma;   Colorectal Cancer (CRC);   Renal Cell Carcinoma (RCC) (Phase ll Only);   Glioblastoma (GBM) (Phase ll Only);   Melanoma (Phase 1 Only)
Intervention: Drug: Combination of varlilumab and nivolumab
31 Recruiting Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Ovarian Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
32 Recruiting A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
Conditions: Malignant Solid Tumour;   Lymphoma, Large B-Cell, Diffuse;   Carcinoma, Non-Small-Cell Lung;   Transitional Cell Carcinoma of Genitourinary Tract;   Triple Negative Breast Cancer;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   Adenocarcinoma of the Endometrium;   Renal Cell Carcinoma
Interventions: Drug: MK-3475;   Drug: INCB024360
33 Recruiting A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Conditions: Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Cervical Cancer;   Renal Cell Carcinoma
Interventions: Drug: MEDI4736;   Drug: Tremelimumab
34 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
35 Active, not recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Anaplastic Oligodendroglioma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Glioblastoma;   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Metastatic Renal Cell Cancer;   Recurrent Adult Brain Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Resectable Hepatocellular Carcinoma;   Sarcoma;   Stage IA Breast Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Corpus Cancer;   Stage IB Breast Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Corpus Cancer;   Stage IC Ovarian Cancer;   Stage II Uterine Corpus Cancer;   Stage IIA Breast Cancer;   Stage IIA Lung Carcinoma;   Stage IIA Ovarian Cancer;   Stage IIB Breast Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Lung Carcinoma;   Stage IIB Ovarian Cancer;   Stage IIB Skin Melanoma;   Stage IIC Ovarian Cancer;   Stage IIC Skin Melanoma;   Stage IIIA Breast Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Skin Melanoma;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sirolimus
36 Terminated HYPAZ: Hypertension Induced by Pazopanib
Conditions: Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Glioblastoma;   Ovarian Cancer;   Cervical Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Pancreatic Cancer;   Melanoma;   Gastrointestinal Cancer
Intervention: Drug: Pazopanib
37 Completed Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Conditions: Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Endometrial Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: temsirolimus;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
38 Withdrawn A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Conditions: Colon Cancer;   Lung Cancer;   Cervical Cancer;   Renal Cell Carcinoma;   Uterine Cancer
Intervention: Drug: (18)Fluciclatide
39 Completed Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Conditions: Pleural Metastases;   Breast Cancer;   Colon Cancer;   Ovarian Cancer;   Uterine Cancer;   Renal Cell Cancer;   Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
40 Active, not recruiting Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Conditions: Extensive Stage Small Cell Lung Cancer;   Hereditary Paraganglioma;   Male Breast Cancer;   Malignant Paraganglioma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus;   Drug: vinorelbine ditartrate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results    Last Page
Indicates status has not been verified in more than two years